BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-8080 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-8080\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07876596-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-8080: Phase 1 readout est. (NCT07876596)
DESCRIPTION:HRS-8080\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080\nEstimated
  primary completion: February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hrs-8080#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07876596
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024173-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07024173)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Loc
 ally Advanced and Metastatic Breast Cancer\nEstimated primary completion: 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 24173
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125950-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HRS-8080: Phase 2 readout est. (NCT07125950)
DESCRIPTION:HRS-8080\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/hrs-8080#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07125950
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-8080: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-8080\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8080: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:HRS-8080\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354022-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07354022)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpici
 clib in Patients With Advanced or Metastatic Breast Cancer Resistant to Ad
 juvant Endocrine Therapy.\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07354022
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349069-11068@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07349069)
DESCRIPTION:HRS-8080\, phase 3.\nStudy: A Phase III Trial Comparing HRS-808
 0 With Standard Endocrine Therapy in Patients With Intermediate or High Ri
 sk Early Breast Cancer\nEstimated primary completion: December 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07349069
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
